	Impact of early versus conventional kidney replacement therapy initiation in tumor lysis syndrome: a target trial emulation. Ann Intensive Care Serre J, Mulier G, Boud'hors C, Lemerle M, Abdel-Nabey M, Orvain C, Chaba A, Biard L, Demiselle J, Zafrani L. PMID: 40180676 [PubMed]
	Prospective Randomised Phase-II Trial of Ipilimumab/Nivolumab versus Standard of Care in non-clear cell Renal Cell Cancer - Results of the SUNNIFORECAST Trial. Ann Oncol Bergmann L, Albiges L, Ahrens M, Gross-Goupil M, Boleti E, Gravis G, Fléchon A, Grimm MO, Bedke J, Barthélémy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Flörcken A, Suarez C, Maroto P, Grünwald V, Oosting SF, Kopecky J, Zschäbitz S, Boegemann M, Buchler T, Niegisch G, Goebell PJ, Waddell T, Joly F, Priou F, Retz M, Siemer S, Zimmermann U, Deckbar D, Burkholder I, Hartmann A, Haanen JB, Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN). PMID: 40180121 [PubMed - as supplied by publisher]
	Standardisation of radiotherapy to inguinal and pelvic lymph nodes in locally-advanced cancer of the penis, as defined by the International Penile Advanced Cancer Trial (InPACT). Int J Radiat Oncol Biol Phys Cooper S, Nicholson S, Crook J, Watkin N, Pettaway C, Barber J, Mitra AV, Woodley O, Millin A, Hall E, Pathmanathan A, Penegar S, Burnett S, Spiess PE, Miles E, Hoffman K, Yang H, Tree A. PMID: 40180061 [PubMed - as supplied by publisher]
	First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet Oncol Fay AP, Fizazi K, Matsubara N, Azad AA, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Cislo P, Chang J, Healy CG, Niyazov A, Agarwal N. PMID: 40179907 [PubMed - indexed for MEDLINE]
	First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet Oncol Matsubara N, Azad AA, Agarwal N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Cislo P, Chang J, Healy CG, Niyazov A, Fizazi K. PMID: 40179906 [PubMed - indexed for MEDLINE]
	[Gender-specific differences in urological tumours]. Aktuelle Urol Weiss J, Laukhtina E, Resch I, Shariat SF. PMID: 40179871 [PubMed - indexed for MEDLINE]
	Using mpMRI, PSMA, and GRPR PET to Assess Focal Therapy Eligibility and Plan Treatment in Biopsy-proven Low-/Intermediate-risk Prostate Cancer: A Whole-mount Pathology-based Study. Clin Nucl Med Li Y, Yang J, Xiao L, Zhou M, Gao X, Rominger A, Shi K, Seifert R, Cai Y, Tang Y, Hu S. PMID: 40179293 [PubMed - indexed for MEDLINE]
	Insulin resistance: a paradoxical protector against low-grade prostate cancer? Findings from the REDUCE trial. Postgrad Med J Desai R, Jain A. PMID: 40179135 [PubMed - as supplied by publisher]
	Study protocol: LIAM Mc trial (Linking In with Advice and supports for Men impacted by Metastatic cancer). PLoS One Noonan B, Bredin P, Cahill AM, Corkery S, Johnston KE, Medved K, Cusack AM, Hegarty J, Saab MM, Cushen SJ, Connolly R, Palmer B, Dahly D, Murphy M, Bambury RM, Gleeson JP. PMID: 40179061 [PubMed - indexed for MEDLINE]
	Identification of ferroptosis-related gene signatures as a novel prognostic model for clear cell renal cell carcinoma. Discov Oncol Du X, Cao H, Zhou YJ, Kong Q, Zhang X. PMID: 40178680 [PubMed]
	Oxidative stress as a catalyst in prostate cancer progression: unraveling molecular mechanisms and exploring therapeutic interventions. Discov Oncol Song Y, Hou Z, Zhu L, Chen Y, Li J. PMID: 40178629 [PubMed]
	"I've got plenty of energy when I'm doing something I want to do": applying self-determination theory to exercise motivation in people with prostate cancer. Support Care Cancer Naismith H, Dhillon HM, Hunter J, Bultijnck R, Kneebone A, Hruby G, Eade T, Parker L, Campbell R, Yee J. PMID: 40178616 [PubMed - indexed for MEDLINE]
	RNF112 Facilitates Ubiquitin-Mediated Degradation of c-Myc, Suppressing Proliferation, Migration and Lipid Synthesis in Bladder Cancer. Adv Sci (Weinh) Xiong K, Chen S, Xu H, Tu S, Weng H, Wang Y, Li M, Yu J, Qian K, Ju L, Zhang Y, Xiao Y, Wang X, Wang G. PMID: 40178292 [PubMed - as supplied by publisher]
	Preoperative CT radiomics-based model for predicting Ki-67 expression in clear cell renal cell carcinoma patients. Zhong Nan Da Xue Xue Bao Yi Xue Ban Yang Z, He H, Zhang Y, Wang J, Zhang W, Zhou F. PMID: 40177755 [PubMed - indexed for MEDLINE]
	The safety and efficacy of BCG combined with mitomycin C compared with BCG monotherapy in patients with non-muscle-invasive bladder cancer: A systematic review and meta-analysis. Open Med (Wars) Liu J, Zhou W, Zhang W, Chang C, Zhang P, Fu G. PMID: 40177654 [PubMed]
	Key immune cells and their crosstalk in the tumor microenvironment of bladder cancer: insights for innovative therapies. Explor Target Antitumor Ther Di Spirito A, Balkhi S, Vivona V, Mortara L. PMID: 40177538 [PubMed]
	Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation. BMJ Oncol Dodkins J, Cook A, Mayne E, Parry M, Nossiter J, Payne H, Cowling TE, Tree A, Aggarwal A, Clarke N, van der Meulen J. PMID: 40177173 [PubMed]
	Performance of PCA3 and TMPRSS2:ERG Within the Prostate Cancer Prevention Trial Risk Calculator Version 2 in a Lithuanian Cohort. Res Rep Urol Kemesiene J, Nicolau C, Cholstauskas G, Zviniene K, Lopeta M, Veneviciute S, Asmenaviciute I, Tamosauskaite K, Pikuniene I, Jievaltas M. PMID: 40176971 [PubMed]
	First pediatric case of spermatic cord fibrolipoma: case report and literature review. BMC Urol Mansiroglu AK, Duman A, Deniz S. PMID: 40176030 [PubMed - indexed for MEDLINE]
	Development and validation of a framework for registration of whole-mount radical prostatectomy histopathology with three-dimensional transrectal ultrasound. BMC Urol Jager A, Zwart MJ, Postema AW, van den Kroonenberg DL, Zwart W, Beerlage HP, Oddens JR, Mischi M. PMID: 40175990 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 166171

Page 1 of 8309



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy